Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Kanjuh, Vladimir I. (57213201627)"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Dabigatran - Metabolism, pharmacologic properties and drug interactions
    (2017)
    Antonijevic, Nebojsa M. (6602303948)
    ;
    Zivkovic, Ivana D. (56487419800)
    ;
    Jovanovic, Ljubica M. (56583764700)
    ;
    Matic, Dragan M. (25959220100)
    ;
    Kocica, Mladen J. (6507502534)
    ;
    Mrdovic, Igor B. (10140828000)
    ;
    Kanjuh, Vladimir I. (57213201627)
    ;
    Culafic, Milica D. (55881915300)
    Background: The superiority of dabigatran has been well proven in the standard dosing regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and extended venous thromboembolism (VTE) treatment. Dabigatran, an anticoagulant with a good safety profile, reduces intracranial bleeding in patients with atrial fibrillation and decreases major and clinically relevant non-major bleeding in acute VTE treatment. However, several important clinical issues are not fully covered by currently available directions with regard to dabigatran administration. The prominent one is reflected in the fact that dynamic impairment in renal function due to dehydratation may lead to haemorragic complications on the one hand, while on the other hand glomerular hyperfiltration may be a possible cause of dabigatran subdosing, hence reducing the drug’s efficacy. Furthermore, limitations of the Cockcroft-Gault formula, considered a standard equation for assessing the renal function, may imply that other calculations are likely to obtain more accurate estimates of the kidney function in specific patient populations. Method and Conclusions: Although not routinely recommended, a possibility of monitoring dabigatran in special clinical settings adds to optimization of its dosage regimens, timely perioperative care and administration of urgently demanded thrombolytic therapy, therefore significantly improving this drug’s safety profile. Despite the fact that dabigatran has fewer reported interactions with drugs, food constituents, and dietary supplements, certain interactions still remain, requiring considerable caution, notably in elderly, high bleeding risk patients, patients with decreased renal function and those on complex drug regimens. Additionally, upon approval of idarucizumab, an antidote to dabigatran solution, hitherto being a major safety concern, has been finally reached, which plays a vital role in life-threatening bleeding and emergency interventions and surgery. © 2017 Bentham Science Publishers.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Giant pseudoaneurysm from Vieussens' arterial ring
    (2004)
    Kocica, Mladen J. (6507502534)
    ;
    Vranes, Mile R. (6701667966)
    ;
    Djukic, Petar L. (6508205447)
    ;
    Mikic, Aleksandar Dj. (57214281171)
    ;
    Velinovic, Milos M. (6507311576)
    ;
    Havelka, Marija (7004544911)
    ;
    Kanjuh, Vladimir I. (57213201627)
    A giant coronary pseudoaneurysm of uncertain cause, arising from Vieussens' arterial ring, was preoperatively diagnosed in an oligosymptomatic female patient. Successful off-pump surgical excision without additional bypass grafting was performed. Difficulties in diagnostic algorithm, as well as possible cause and extremely rare localization were discussed. © 2004 by The Society of Thoracic Surgeons.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The effects of potassium channel opener P1075 on the human saphenous vein and human internal mammary artery
    (2011)
    Gojkovic-Bukarica, Ljiljana C. (6602830901)
    ;
    Beleslin-Cokic, Bojana B. (6506788366)
    ;
    Novakovic, Aleksandra N. (6602915174)
    ;
    Peric, Miodrag S. (7006618529)
    ;
    Markovic-Lipkovski, Jasmina Z. (6603725388)
    ;
    Cirovic, Sanja Z. (36027425000)
    ;
    Nezic, Dusan G. (6701705512)
    ;
    Lesic, Aleksandar R. (55409413400)
    ;
    Kanjuh, Vladimir I. (57213201627)
    ;
    Heinle, Helmut (7003342814)
    Because adrenergic contractions can contribute to the development of life-threatening spasm of coronary artery bypass graft, this study was performed to investigate the effect of adenosine 3-phosphate (ATP)-sensitive K channel (KATP) opener P1075 on contractions of isolated human saphenous vein (HSV) and human internal mammary artery (HIMA). Phasic contractions were evoked by electric field stimulation (20 Hz) and noradrenaline. The sustained contractions were evoked by phenylephrine. The presence of pore-forming Kir6.1 and Kir6.2 subunits of the KATP channels in the HIMA and only Kir6.2 in the HSV was confirmed immunomorphologically. P1075 inhibited in the HSV only, the electrical field stimulation contractions more strongly than noradrenaline contractions. In addition, the phenylephrine contractions of HSV were more sensitive to P1075 in comparison to those of HIMA. Glibenclamide, a K ATP channel blocker antagonized the vasodilatation produced by P1075 in both grafts differently, because its effect was more prominent on the P1075-induced inhibition of contractions of HSV than of HIMA. We conclude that P1075 has a vasorelaxant effect and inhibited adrenergic contractions of the tested grafts. This effect is graft and vasoconstrictor selective and seems to be mediated by Kir6.1- and/or Kir6.2-containing KATP channels. Thus, P1075 can be considered as a potential drug in the prevention of graft spasm. © 2011 by Lippincott Williams & Wilkins.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    The effects of potassium channel opener P1075 on the human saphenous vein and human internal mammary artery
    (2011)
    Gojkovic-Bukarica, Ljiljana C. (6602830901)
    ;
    Beleslin-Cokic, Bojana B. (6506788366)
    ;
    Novakovic, Aleksandra N. (6602915174)
    ;
    Peric, Miodrag S. (7006618529)
    ;
    Markovic-Lipkovski, Jasmina Z. (6603725388)
    ;
    Cirovic, Sanja Z. (36027425000)
    ;
    Nezic, Dusan G. (6701705512)
    ;
    Lesic, Aleksandar R. (55409413400)
    ;
    Kanjuh, Vladimir I. (57213201627)
    ;
    Heinle, Helmut (7003342814)
    Because adrenergic contractions can contribute to the development of life-threatening spasm of coronary artery bypass graft, this study was performed to investigate the effect of adenosine 3-phosphate (ATP)-sensitive K channel (KATP) opener P1075 on contractions of isolated human saphenous vein (HSV) and human internal mammary artery (HIMA). Phasic contractions were evoked by electric field stimulation (20 Hz) and noradrenaline. The sustained contractions were evoked by phenylephrine. The presence of pore-forming Kir6.1 and Kir6.2 subunits of the KATP channels in the HIMA and only Kir6.2 in the HSV was confirmed immunomorphologically. P1075 inhibited in the HSV only, the electrical field stimulation contractions more strongly than noradrenaline contractions. In addition, the phenylephrine contractions of HSV were more sensitive to P1075 in comparison to those of HIMA. Glibenclamide, a K ATP channel blocker antagonized the vasodilatation produced by P1075 in both grafts differently, because its effect was more prominent on the P1075-induced inhibition of contractions of HSV than of HIMA. We conclude that P1075 has a vasorelaxant effect and inhibited adrenergic contractions of the tested grafts. This effect is graft and vasoconstrictor selective and seems to be mediated by Kir6.1- and/or Kir6.2-containing KATP channels. Thus, P1075 can be considered as a potential drug in the prevention of graft spasm. © 2011 by Lippincott Williams & Wilkins.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback